NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

Moderna Covid vaccine approved for those 12-64 with risk factors Moderna expects mNEXSPIKE to be ready for 2025-2026 season ...

The US FDA has approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for use in adults aged 65 and older.

Citing concerns about mRNA technology, the Trump administration has pulled funding for a vaccine, even though Moderna says it ...

Oddly, the number of Hungarians seeking medical help for an acute respiratory infection has risen for the second week in a ...

A new COVID-19 variant is spreading in the U.S. Will there be a summer surge? Experts discuss current COVID trends, symptoms, ...

In a letter sent Tuesday, Sen. Lisa Blunt Rochester (D-Del.) demanded that health secretary Robert Kennedy clarify whether ...

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...